专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004110349A3 SARS T CELL EPITOPES AND METHODS FOR IDENTIFYING SAME 审中-公开
标题翻译： SARS T细胞抗体及其鉴定方法
公开(公告)号：WO2004110349A3
公开(公告)日：2006-03-23
申请号：PCT/US2004015026
申请日：2004-05-14
申请人： SIGA TECHNOLOGIES INC , NIELSEN MORTEN , LUND OLE , LUNDEGAARD CLAUS , WORNING PEDER , BUUS SOREN , BRUNAK SOREN , JUSTESEN SUNE , SYLVESTER-HVID CHRISTINA , RODER GUSTAV A , LAMBERTH KASPER
发明人： NIELSEN MORTEN , LUND OLE , LUNDEGAARD CLAUS , WORNING PEDER , BUUS SOREN , BRUNAK SOREN , JUSTESEN SUNE , SYLVESTER-HVID CHRISTINA , RODER GUSTAV A , LAMBERTH KASPER
IPC分类号： A61K20060101 , A61K39/215 , C07K14/165 , C07K7/06 , C12Q1/70
CPC分类号： A61K39/215 , A61K39/12 , A61K2039/53 , C07K14/005 , C12N2770/20022 , C12N2770/20034 , G01N2333/165
摘要： In a first aspect the present invention consists of T cell epitopes in the Severe Acute Respiratory Syndrome (SARS) virus genome. More specifically there is provided 180 class I linear peptide epitopes and 200 class II linear epitopes from the SARS Virus genome. In a second aspect the invention also consists of variants of these sequences. In a third aspect this invention consists of a method to predict these sequences from genome data and to validate the predications experimentally. In a fourth aspect the present invention provides compositions including these epitopes for use in a vaccine and to induce a T cell response in a subject, or as a diagnostic tool.
摘要翻译：在第一方面，本发明由严重急性呼吸综合征（SARS）病毒基因组中的T细胞表位构成。更具体地，提供了来自SARS病毒基因组的180个I类线性肽表位和200个II类线性表位。在第二方面，本发明也由这些序列的变体组成。在第三方面，本发明包括从基因组数据预测这些序列并通过实验来验证预测的方法。在第四方面，本发明提供包含用于疫苗的这些表位并诱导受试者的T细胞应答或作为诊断工具的组合物。

2. 发明申请

WO2004072112A3 A METHOD FOR FORMULATING MHC-LIKE MOLECULES FOR LONG TIME STORAGE 审中-公开
标题翻译：用于长时间存储的用于制备MHC样分子的方法
公开(公告)号：WO2004072112A3
公开(公告)日：2004-09-16
申请号：PCT/DK2004000094
申请日：2004-02-11
申请人： UNIV KOEBENHAVN , BUUS SOEREN , SYLVESTER-HVID CHRISTINA
发明人： BUUS SOEREN , SYLVESTER-HVID CHRISTINA
IPC分类号： C07K14/74 , C07K14/705 , G01N33/68
CPC分类号： C07K14/70539
摘要： The present invention describes how MHC-like molecules can be formulated in an active form and stored under conditions, which preserve their activity for an extended period of time, while readily allowing the end-user to generate any ligand-MHC-complex of their choice. The present inventors have termed the product of this invention: "formulated MHC molecules". The utility of such formulated MHC molecules is considerable. One has to keep in mind that an entire arm of the immune system, the T cell immune system, is based upon the recognition of ligands selected and presented by MHC molecules. These ligands constitute the targets of the cellular immune system. They include foreign targets such as vaccine and/or immunotherapy candidates, who can be used to direct immunity against infectious agents and cancers, as well as self-targets involved in the development of autoimmune diseases and transplantation reactions. The availability of formulated MHC molecules affords a non-expert end-user with the enabling technology to identify and validate MHC ligands, and subsequently to generate specific ligand-MHC-complexes for the identification, validation, selection, and induction of specific T cells. The present invention therefore facilitates specific analysis and manipulation of the immune system.
摘要翻译：本发明描述了如何将MHC样分子配制成活性形式并在条件下储存，其在长时间保持其活性的同时容易地允许最终用户产生其选择的任何配体-MHC-复合物。本发明人已经将本发明的产品称为“配制的MHC分子”。这种配制的MHC分子的效用是相当大的。人们必须记住，免疫系统的全部臂，T细胞免疫系统，是基于由MHC分子选择和呈现的配体的识别。这些配体构成细胞免疫系统的靶标。它们包括诸如疫苗和/或免疫治疗候选物的外来靶标，其可用于引导针对感染因子和癌症的免疫，以及涉及自身免疫疾病和移植反应发展的自身靶标。配制的MHC分子的可用性为非专家终端用户提供了启用技术来鉴定和验证MHC配体，并随后产生用于鉴定，验证，选择和诱导特异性T细胞的特异性配体-MHC-复合物。因此，本发明有助于免疫系统的特异性分析和操作。

3. 发明申请

WO2004072112A2 A METHOD FOR FORMULATING MHC-LIKE MOLECULES FOR LONG TIME STORAGE 审中-公开
标题翻译：用于长时间储存的MHC样分子的制备方法
公开(公告)号：WO2004072112A2
公开(公告)日：2004-08-26
申请号：PCT/DK2004/000094
申请日：2004-02-11
申请人： KØBENHAVNS UNIVERSITET , BUUS, Søren , SYLVESTER-HVID, Christina
发明人： BUUS, Søren , SYLVESTER-HVID, Christina
IPC分类号： C07K14/705
CPC分类号： C07K14/70539
摘要： The present invention describes how MHC-like molecules can be formulated in an active form and stored under conditions, which preserve their activity for an extended period of time, while readily allowing the end-user to generate any ligand-MHC-complex of their choice. The present inventors have termed the product of this invention: “formulated MHC molecules”. The utility of such formulated MHC molecules is considerable. One has to keep in mind that an entire arm of the immune system, the T cell immune system, is based upon the recognition of ligands selected and presented by MHC molecules. These ligands constitute the targets of the cellular immune system. They include foreign targets such as vaccine and/or immunotherapy candidates, who can be used to direct immunity against infectious agents and cancers, as well as self-targets involved in the development of autoimmune diseases and transplantation reactions. The availability of formulated MHC molecules affords a non-expert end-user with the enabling technology to identify and validate MHC ligands, and subsequently to generate specific ligand-MHC-complexes for the identification, validation, selection, and induction of specific T cells. The present invention therefore facilitates specific analysis and manipulation of the immune system.
摘要翻译：本发明描述了MHC样分子如何能够以活性形式配制并且在能够长时间保存其活性的条件下储存，同时容易使终端用户产生任何他们选择的配体-MHC-复合物。本发明人称之为本发明的产品：“配制的MHC分子”。这种配制的MHC分子的效用是相当可观的。人们必须记住，免疫系统的整个组成部分--T细胞免疫系统是基于识别由MHC分子选择和呈递的配体。这些配体构成细胞免疫系统的靶标。它们包括外来目标，如疫苗和/或免疫疗法候选物，可用于指导针对传染性病原体和癌症的免疫力，以及涉及自身免疫疾病和移植反应发展的自我靶标。配制的MHC分子的可用性为非专业最终用户提供了启动技术来鉴定和验证MHC配体，并随后产生用于特异性T细胞的鉴定，验证，选择和诱导的特异性配体-MHC-复合物。因此，本发明便于对免疫系统进行特定的分析和操作。

4. 发明申请

WO2004110349A2 T CELL EPITOPES USEFUL IN A SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS VACCINE AND AS DIAGNOSTIC TOOLS AND METHODS FOR IDENTIFYING SAME 审中-公开
标题翻译：严重急性呼吸道综合征（SARS）病毒疫苗和诊断工具中的T细胞抗原决定因子及其鉴定方法
公开(公告)号：WO2004110349A2
公开(公告)日：2004-12-23
申请号：PCT/US2004/015026
申请日：2004-05-14
申请人： SIGA TECHNOLOGIES, INC. , NIELSEN, Morten , LUND, Ole , LUNDEGAARD, Claus , WORNING, Peder , BUUS, Soren , BRUNAK, Soren , JUSTESEN, Sune , SYLVESTER-HVID, Christina , RODER, Gustav, A. , LAMBERTH, Kasper
发明人： NIELSEN, Morten , LUND, Ole , LUNDEGAARD, Claus , WORNING, Peder , BUUS, Soren , BRUNAK, Soren , JUSTESEN, Sune , SYLVESTER-HVID, Christina , RODER, Gustav, A. , LAMBERTH, Kasper
IPC分类号： A61K
CPC分类号： A61K39/215 , A61K39/12 , A61K2039/53 , C07K14/005 , C12N2770/20022 , C12N2770/20034 , G01N2333/165
摘要： In a first aspect the present invention consists of T cell epitopes in the Severe Acute Respiratory Syndrome (SARS) virus genome. More specifically there is provided 180 class I linear peptide epitopes and 200 class II linear epitopes from the SARS Virus genome. In a second aspect the invention also consists of variants of these sequences. In a third aspect this invention consists of a method to predict these sequences from genome data and to validate the predications experimentally. In a fourth aspect the present invention provides compositions including these epitopes for use in a vaccine and to induce a T cell response in a subject, or as a diagnostic tool.
摘要翻译：在第一方面，本发明由严重急性呼吸综合征（SARS）病毒基因组中的T细胞表位组成。更具体地说，提供了来自SARS病毒基因组的180个I类线性肽表位和200个II类线性表位。在第二方面，本发明也由这些序列的变体组成。在第三方面，本发明包括从基因组数据预测这些序列并通过实验来验证预测的方法。在第四方面，本发明提供包含用于疫苗的这些表位并诱导受试者的T细胞应答或作为诊断工具的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式